Psychiatry

Neuroscience innovation
#AI #Alzheimer's #Artificial intelligence (AI) #Biomarkers #Brain disease #Drug discovery #Inherited tauopathies #Mental health #Nervous system disorders #Neurodegenerative disorders #Neurology #Neuroscience #Neurotechnology #Psychiatry #Tau protein

New podcast on innovation in neuroscience

This is the latest episode of the free DDW narrated podcast, titled “Where is the latest innovation in neuroscience?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Taking a new approach to tackle neurodegenerative diseases,… Read More

#News

Long Covid
#Covid-19 #Immunology #Long Covid #Psychiatry #SARS-CoV-2

New post-Covid study links infection and retrovirus 

A Translational Psychiatry publication indicates that SARS-CoV-2 infection, even when unnoticed or asymptomatic, can have an influence on the activation of the Human Endogenous Retrovirus W (W-ENV) protein in psychotic patients, in a context of innate immune inflammation.   GeNeuro, a biopharmaceutical company developing treatments… Read More

#Covid-19 #News

Human brain
#AlzeCure Pharma #Antidepressants #Depression #Preclinical investigations #Psychiatry

Preclinical study proves antidepressant effects of drug

The results of a preclinical study supporting the antidepressive effects of AlzeCure Pharma’s NeuroRestore ACD856 have been published in the journal Psychopharmacology. The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various… Read More

#Editor's Choice #News

Mental health
#Antidepressants #Anxiety disorder #Depression #Drug discovery #Mental health #Neuroscience #Psychiatry

World Wellbeing Week 2023: Celebrating drug discovery innovation

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. World Wellbeing Week was created to celebrate the many aspects of wellbeing, from meaningful, purposeful work to financial security, physical, mental and emotional health, social resilience and empathic corporate and civic leadership, community relations… Read More

#Exclusive Content

Hormones in the brain concept
#Antidepressants #Depression #Evecxia Therapeutics #Major depressive disorder #Phase I trial #Psychiatry

New adjunctive antidepressant elevates serotonin in Phase I trial

Evecxia Therapeutics has reported favourable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a Phase I trial of EVX-101 in healthy volunteers treated with escitalopram. The company is also planning a Phase II adjunctive EVX-101 trial in patients with major depressive disorder (MDD) responding inadequately to a… Read More

#News

Female medical researcher
#Genetics #Genetics / genomics #Icahn School of Medicine #Neuroscience #Psychiatry #Schizophrenia

Researchers identify genes that may increase schizophrenia risk

Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-centre study further demonstrated that the schizophrenia risk conferred by these… Read More

#News

Dr Yue Wang and Professor Jianhua Guo
#Antibiotic resistance #Antibiotics #Antidepressants #Antimicrobial resistance (AMR) #Psychiatry

Common antidepressants increase antibiotic resistance

Researchers have found a range of commonly prescribed antidepressants can increase bacteria’s resistance to antibiotic medications. A study led by Professor Jianhua Guo from University of Queensland’s Australian Centre for Water and Environmental Biotechnology focused on prescription drugs used to treat depressive disorders, anxiety disorders, and other psychological… Read More

#News

Patient speaking to psychiatrist
#Alta Neuroscience #Biomarkers #Major depressive disorder #Neuroscience #Phase II trial #Precision psychiatry #Psychiatry

Precision drug could redefine depression treatment

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a… Read More

#News

Nasal spray
#Beckley Psytech #Depression #Phase II trial #Psychiatry #Treatment-resistant depression

Phase IIa study begins in treatment resistant depression

Beckley Psytech has initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for treatment resistant depression (TRD).  Depression affects around 280 million people around the world, but 30% of those living with the condition are resistant to available antidepressant medications,… Read More

#News

5-Methoxy-N, N-Dimethyltryptamine
#Phase I trial #Psychedelics #Psychiatry #Treatment-resistant depression

Synthetic psychedelic successfully completes Phase I study 

Beckley Psytech has completed its Phase I clinical study of BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT).  The drug is under development for Treatment Resistant Depression and Alcohol Use Disorder and was assessed in combination with psychological support in 44 psychedelic-naïve participants.  Initial… Read More

#News

#Interview #Mental health #Neuroscience #Precision psychiatry #Psychiatry #Psychiatry Consortium #Target identification #Target validation

Target validation in psychiatry: addressing unmet therapeutic needs

The Psychiatry Consortium and the British Neuroscience Association recently published their 'Guiding Principles for Robust Target Validation in Psychiatry'. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new therapeutic… Read More

#Exclusive Content

Neurons in the brain
#Antidepressants #Interview #Major depressive disorder #Neuropsychiatric disorders #Neuroscience #Precision medicine #Precision psychiatry #Psychiatry

Precision psychiatry: Transforming therapeutics for CNS disorders

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our understanding… Read More

#Exclusive Content

#AI #Biopharmaceuticals #Collaboration #Neuroscience #Psychiatry #Therapeutics

Collaboration extended in severe neuropsychiatric disorders 

Clinical-stage biopharmaceutical company Karuna Therapeutics has extended its drug discovery collaboration with PsychoGenics, AI-enabled phenotypic drug discovery and preclinical CRO services.  The collaboration aims to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.  The initial multi-year agreement, announced in July 2020,… Read More

#News

Patient reported outcomes
#Biomarkers #Mental health #Neurodegenerative disorders #Neurology #Neuroscience #Psychiatry

The rise of digital biomarkers in neuroscience drug development 

Listen to this article on the DDW Podcast: Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J Mark Treherne, Dr Jenny Barnett and Dr Paula Moran.  Increasingly, digital biomarkers are becoming more effectively used in the discovery and… Read More

#Editor's Choice #Exclusive Content